In this episode of Psychedelic Spotlight, Matt sits down with Rob Barrow, CEO of MindMed (NASDSAQ: MNMD, NEO:MMED). MindMed is a psychedelic medicines company working with substances such as LSD, MDMA, psilocybin and more, to help treat a variety of mental health conditions.

In this interview, many topics are touched upon. The two start the conversation on the neuroscience of psychedelics, and it quickly shifts to the nature of consciousness.
Later, topics such as psychedelics culture, art and philosophy.

Of course, Barrow also discusses MindMed’s clinical trials and their drug development pipeline.
Can LSD treat anxiety? Can 18-MC treat addiction? Can MDMA be mixed safely with LSD? These are all questions MindMed is researching.

What are the ethics of the Big pharma industry entering the psychedelics industry? Barrow has an enlightened answer on the question. In the end, the pharma industry needs to put the patient at the center of the discussion.

At the end of the day, psychedelic therapy research is all about helping patients conquer their mental health problems. This means addressing not only the development of psychedelic drugs, but also how to scale up up therapy so that it is accessible.

#MindMed #Neuroscience #Psychedelics

source

Similar Posts

Interview With Steven Huang, DEI Consultant at MAPS and Numinus

Interview With Steven Huang, DEI Consultant at MAPS and Numinus

Listen, Podcasts

Steven’s consultancy company, Millennial HR Design, focuses on the intersection of DEI and psychedelics, where he intends to be a leverage point for the psychedelics industry to better understand their impact on marginalized communities. With nearly 10 years of industry experience, Steven hopes for more diverse and equitable representation in the psychedelic space. 

Mendeleyev: Music, Magic, Mushrooms

Mendeleyev: Music, Magic, Mushrooms

Listen

In the realm where music meets the mystical, few artists embody the fusion of psychedelic exploration and sonic innovation like Mendeleyev.

MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]

MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]

Listen, Videos

Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode.

Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating.
Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do?
Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s.

On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So….

In this segment, we’ll discuss FOUR possible cases:
Timestamps:
0:00 – Intro
4:17 – Worst Case
7:48 – Probable Case
9:57 – #WINNING CASE
11:58 – APES TOGETHER STRONG CASE

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedNasdaq #MindMedstock

Interview With Carlos Tanner

Interview With Carlos Tanner

Listen, Podcasts

In this episode, Global Trac Solutions, Inc. CEO, David Flores, has the very distinct pleasure of being joined by Carlos Tanner, founder of the Ayahuasca Foundation in Iquitos, Peru.